Roche drugs show limited benefit in lung, breast cancer trials

Roche drugs show limited benefit in lung, breast cancer trials


In a disappointment for Roche Holding AG, two of its oncology drugs provided only modest protection from disease progression in lung cancer and breast cancer, according to data from separate clinical trials presented on Saturday. Adding Roche's high-profile immunotherapy Tecentriq to other standard cancer drugs extended by only about three weeks the median time patients with advanced squamous cell lung cancer lived before their disease progressed in one late stage study.



from Biotech News